New cancer drug CTX-10726 enters first human tests

NCT ID NCT07419841

Recruiting now Disease control Sponsor: Compass Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 4 times

Summary

This early-stage trial tests an experimental drug called CTX-10726 in about 70 people with advanced gastroesophageal, liver, endometrial, or kidney cancers that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug by IV every two weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CTX-10726 (an experimental drug given by IV infusion every two weeks)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 70 participants, so the drug may not prove safe or effective. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm gastroesophageal cancer hepatocellular carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER GASTROESOPHAGEAL CANCER (GC) HEPATOCELLULAR CARCINOMA (HCC) RENAL CELL CARCINOMA (RCC)

Contacts and locations

Show contact details

Locations

Nebraska Cancer Specialists
RECRUITING

Omaha, Nebraska, 68130, United States
Prisma Health Cancer Institute
RECRUITING

Greenville, South Carolina, 29605, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
START New York
RECRUITING

Lake Success, New York, 11042, United States
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.